OncoSynergy, Inc.
OncoSynergy is a clinical-stage biopharmaceutical company based in Stamford, CT, focused on developing innovative therapies for high unmet need and high value cancers. Their mission is to radically improve cancer patient outcomes through targeted, multi-mechanism therapeutics, including their lead candidate OS2966, a first-in-class anti-CD29 monoclonal antibody. They aim to address the challenges of treating aggressive and resistant cancers, including glioblastoma and ovarian cancer, by targeting fundamental interactions in the tumor microenvironment.
Industries
Nr. of Employees
small (1-50)
OncoSynergy, Inc.
Patents
Products
Clinical-stage monoclonal antibody therapeutic targeting integrin beta-1
A humanized monoclonal antibody biologic developed to modulate integrin beta-1 interactions in the tumor microenvironment, evaluated for treatment of recurrent glioblastoma and other solid and hematologic malignancies in loco‑regional and systemic approaches.
Oncolytic viral vector platform expressing therapeutic antibody fragments
A research-stage oncolytic viral platform engineered to express antibody fragments to enhance oncolytic replication and anti-tumor efficacy in preclinical models.
Clinical-stage monoclonal antibody therapeutic targeting integrin beta-1
A humanized monoclonal antibody biologic developed to modulate integrin beta-1 interactions in the tumor microenvironment, evaluated for treatment of recurrent glioblastoma and other solid and hematologic malignancies in loco‑regional and systemic approaches.
Oncolytic viral vector platform expressing therapeutic antibody fragments
A research-stage oncolytic viral platform engineered to express antibody fragments to enhance oncolytic replication and anti-tumor efficacy in preclinical models.
Services
End-to-end clinical trial services for early‑phase intracerebral biologic studies, including protocol design, neurosurgical delivery using convection-enhanced delivery and multiport catheters, enrollment coordination for patients requiring resection, and acquisition of infused tumor tissue for pharmacodynamic analysis.
Management of outsourced cell line development, upstream/downstream process optimization, analytical characterization, formulation development and GMP manufacture through contract development and manufacturing organizations to produce IND‑enabling and clinical‑grade biologic material.
Research and development of oncolytic viral vectors engineered to express therapeutic antibody fragments and preclinical testing of viral replication and combination efficacy, supported by non‑dilutive grant funding.
End-to-end clinical trial services for early‑phase intracerebral biologic studies, including protocol design, neurosurgical delivery using convection-enhanced delivery and multiport catheters, enrollment coordination for patients requiring resection, and acquisition of infused tumor tissue for pharmacodynamic analysis.
Management of outsourced cell line development, upstream/downstream process optimization, analytical characterization, formulation development and GMP manufacture through contract development and manufacturing organizations to produce IND‑enabling and clinical‑grade biologic material.
Research and development of oncolytic viral vectors engineered to express therapeutic antibody fragments and preclinical testing of viral replication and combination efficacy, supported by non‑dilutive grant funding.
Expertise Areas
- Phase I clinical trial management for intracerebral biologics
- Neurosurgical loco-regional drug delivery and CED-based administration
- Monoclonal antibody discovery and preclinical development
- GMP biologics process development and CDMO collaboration
Key Technologies
- Monoclonal antibody therapeutics targeting integrin beta-1
- Convection-enhanced delivery (CED)
- Multiport catheter systems for distributed intracerebral infusion
- GMP process development and high‑productivity cell line development
News & Updates
The FDA has granted orphan drug designation for OS2966 in the treatment of acute myeloid leukemia, supporting its development for this rare and aggressive cancer.
The first patient was treated in a Phase 1 trial evaluating OS2966 for recurrent glioblastoma, a challenging brain cancer, delivered via convection-enhanced delivery to bypass the blood-brain barrier.
The company has opened enrollment for a Phase 1 trial of OS2966, a monoclonal antibody targeting Beta1 integrin (CD29), to treat glioblastoma, especially resistant forms.
The FDA has granted orphan drug designation for OS2966 in the treatment of ovarian cancer, in addition to glioblastoma, supporting its development for multiple cancers.
A study led by Dr. Yong-Mi Kim found that OS2966, an anti-CD29 antibody, prolonged survival in preclinical models of acute myeloid leukemia, supporting its potential for this aggressive blood cancer.
The FDA has granted orphan drug designation for OS2966 in the treatment of acute myeloid leukemia, supporting its development for this rare and aggressive cancer.
The FDA has granted orphan drug designation for OS2966 in the treatment of acute myeloid leukemia, supporting its development for this rare and aggressive cancer.
The first patient was treated in a Phase 1 trial evaluating OS2966 for recurrent glioblastoma, a challenging brain cancer, delivered via convection-enhanced delivery to bypass the blood-brain barrier.
The company has opened enrollment for a Phase 1 trial of OS2966, a monoclonal antibody targeting Beta1 integrin (CD29), to treat glioblastoma, especially resistant forms.
The FDA has granted orphan drug designation for OS2966 in the treatment of ovarian cancer, in addition to glioblastoma, supporting its development for multiple cancers.
A study led by Dr. Yong-Mi Kim found that OS2966, an anti-CD29 antibody, prolonged survival in preclinical models of acute myeloid leukemia, supporting its potential for this aggressive blood cancer.
The FDA has granted orphan drug designation for OS2966 in the treatment of acute myeloid leukemia, supporting its development for this rare and aggressive cancer.